 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- || Nabi-HB (hepatitis B immune globulin) / ADMA Biologics, Bivigam (immune globulin intravenous [human]) / ADMA Biologics
$ADMA ADMA Biologics Announces Commercial Availability of Expanded Vial Size Offerings for BIVIGAM® and NABI-HB® https://t.co/K7ucSOmxFV #offering (Twitter) - Aug 9, 2021
- Nabi-HB (hepatitis B immune globulin) / ADMA Biologics
[VIRTUAL] PHARMACOECONOMIC ANALYSIS COMPARING MEDICAL COSTS FOR PROPHYLAXIS OF HIV AND HBV INFECTION IN SEXUAL ASSAULT PATIENTS () - Apr 11, 2021 - Abstract #AMCP2021AMCP_36;
PEP intervention with a hepatitis B immune globulin (HBIG) that has demonstrated efficacy in preventing HBV infection after exposure may provide immediate protective serum concentrations of anti-hepatitis B antibody that cannot be provided by vaccine administration. Revising CDC guidelines to include HBIG intervention in the CDC recommendations for HBV PEP can protect patients from the risk of HBV infection and reduce healthcare expenditures across managed care organizations
- Nabi-HB (hepatitis B immune globulin) / ADMA Biologics
Enrollment change: Nabi-HB-SC: Nabi-HB Administered Subcutaneously in Patients With Hepatitis B Virus Post Liver Transplantation (clinicaltrials.gov) - Jan 19, 2016
P3, N=0, Withdrawn, Sponsor: Biotest Pharmaceuticals Corporation
Revising CDC guidelines to include HBIG intervention in the CDC recommendations for HBV PEP can protect patients from the risk of HBV infection and reduce healthcare expenditures across managed care organizations N=25 --> 0
- | Nabi-HB (hepatitis B immune globulin) / ADMA Biologics
New P1/2 trial, Combination therapy: Pilot Study to Assess the Pharmacokinetics of Intravenous Nabi 5% Hepatitis B Immune Globulin (Boca HBVIg) Used in Combination With Lamivudine for Patients With Hepatitis B Virus (HBV) Associated Liver Disease Undergoing Liver Transplantation (clinicaltrials.gov) - Aug 17, 2011
P1/2, N=30, Completed, Sponsor: Biotest Pharmaceuticals Corporation